Ken Griffin Bluebird Bio, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.47 - $1.35 $14,758 - $42,390	-31,400 Reduced 16.04%	164,400 $85,000
Q2 2024 Aug 14, 2024	BUY	$0.85 - $1.26 $62,390 - $92,484	73,400 Added 59.97%	195,800 $191,000
Q1 2024 May 15, 2024	SELL	$0.91 - $1.75 $255,801 - $491,925	-281,100 Reduced 69.67%	122,400 $156,000
Q4 2023 Feb 14, 2024	BUY	$1.32 - $4.83 $343,728 - $1.26 Million	260,400 Added 181.97%	403,500 $556,000
Q3 2023 Nov 14, 2023	BUY	$3.02 - $4.05 $59,796 - $80,190	19,800 Added 16.06%	143,100 $435,000
Q2 2023 Aug 14, 2023	SELL	$2.79 - $5.03 $119,133 - $214,781	-42,700 Reduced 25.72%	123,300 $405,000
Q1 2023 May 15, 2023	SELL	$3.14 - $8.22 $332,526 - $870,498	-105,900 Reduced 38.95%	166,000 $527,000
Q4 2022 Feb 14, 2023	SELL	$5.77 - $8.49 $55,391 - $81,504	-9,600 Reduced 3.41%	271,900 $1.88 Million
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $596,625 - $1.18 Million	159,100 Added 129.98%	281,500 $1.78 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.